DE602008005457D1 - Antitumor-kombinationen mit einem vegf-hemmenden mittel und irinotecan - Google Patents

Antitumor-kombinationen mit einem vegf-hemmenden mittel und irinotecan

Info

Publication number
DE602008005457D1
DE602008005457D1 DE602008005457T DE602008005457T DE602008005457D1 DE 602008005457 D1 DE602008005457 D1 DE 602008005457D1 DE 602008005457 T DE602008005457 T DE 602008005457T DE 602008005457 T DE602008005457 T DE 602008005457T DE 602008005457 D1 DE602008005457 D1 DE 602008005457D1
Authority
DE
Germany
Prior art keywords
inhibitable
irinotecan
vegf
agent
antitumor combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602008005457T
Other languages
English (en)
Inventor
Marie-Christine Bissery
Marielle Chiron-Blondel
Pascale Lejeune
Patricia Vrignaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38961256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602008005457(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE602008005457D1 publication Critical patent/DE602008005457D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE602008005457T 2007-07-05 2008-07-02 Antitumor-kombinationen mit einem vegf-hemmenden mittel und irinotecan Active DE602008005457D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704868A FR2918279B1 (fr) 2007-07-05 2007-07-05 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
PCT/FR2008/000943 WO2009024667A2 (fr) 2007-07-05 2008-07-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan

Publications (1)

Publication Number Publication Date
DE602008005457D1 true DE602008005457D1 (de) 2011-04-21

Family

ID=38961256

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602008005457T Active DE602008005457D1 (de) 2007-07-05 2008-07-02 Antitumor-kombinationen mit einem vegf-hemmenden mittel und irinotecan

Country Status (24)

Country Link
US (3) US20100160233A1 (de)
EP (1) EP2173349B1 (de)
JP (4) JP2010532335A (de)
KR (4) KR20180105261A (de)
CN (3) CN101686975A (de)
AR (1) AR067420A1 (de)
AT (1) ATE500829T1 (de)
AU (1) AU2008290442B2 (de)
BR (1) BRPI0812835B8 (de)
CA (1) CA2693152C (de)
CY (1) CY1111675T1 (de)
DE (1) DE602008005457D1 (de)
DK (1) DK2173349T3 (de)
ES (1) ES2362637T3 (de)
FR (1) FR2918279B1 (de)
HR (1) HRP20110432T1 (de)
IL (2) IL203132A (de)
MX (1) MX2009013950A (de)
PL (1) PL2173349T3 (de)
PT (1) PT2173349E (de)
RS (1) RS51777B (de)
RU (1) RU2471483C2 (de)
SI (1) SI2173349T1 (de)
WO (1) WO2009024667A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367615B (es) 2002-09-06 2019-08-28 Cerulean Pharma Inc Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
EP2344161B1 (de) * 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Kombinationen eines liposomalen wasserlöslichen camptothecins mit cetuximab oder bevacizumab
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US20130029909A1 (en) * 2009-09-15 2013-01-31 John Ryan Treatment of cancer
SG191334A1 (en) 2011-01-13 2013-08-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515913A (en) * 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
KR20040091083A (ko) * 2002-03-01 2004-10-27 파마시아 이탈리아 에스.피.에이. 이리노테칸 히드로클로라이드의 결정성 다형체
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
AU2005265071A1 (en) * 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

Also Published As

Publication number Publication date
DK2173349T3 (da) 2011-06-27
WO2009024667A2 (fr) 2009-02-26
KR20180105261A (ko) 2018-09-27
SI2173349T1 (sl) 2011-06-30
CN101686975A (zh) 2010-03-31
JP2014240422A (ja) 2014-12-25
CN103623392A (zh) 2014-03-12
US20190275147A1 (en) 2019-09-12
BRPI0812835B1 (pt) 2020-09-08
BRPI0812835B8 (pt) 2021-05-25
JP2010532335A (ja) 2010-10-07
IL203132A (en) 2015-09-24
FR2918279A1 (fr) 2009-01-09
CN105833244A (zh) 2016-08-10
RS51777B (en) 2011-12-31
AR067420A1 (es) 2009-10-07
KR20150048910A (ko) 2015-05-07
CA2693152A1 (fr) 2009-02-26
ES2362637T3 (es) 2011-07-08
RU2471483C2 (ru) 2013-01-10
JP2017052789A (ja) 2017-03-16
PL2173349T3 (pl) 2011-08-31
FR2918279B1 (fr) 2010-10-22
HRP20110432T1 (hr) 2011-07-31
EP2173349A2 (de) 2010-04-14
WO2009024667A3 (fr) 2009-04-23
ATE500829T1 (de) 2011-03-15
US20100160233A1 (en) 2010-06-24
PT2173349E (pt) 2011-06-02
KR20160079918A (ko) 2016-07-06
RU2010103781A (ru) 2011-08-10
CA2693152C (fr) 2019-02-26
AU2008290442B2 (en) 2013-06-27
CY1111675T1 (el) 2015-10-07
KR20100031123A (ko) 2010-03-19
BRPI0812835A2 (pt) 2014-12-09
JP2019006785A (ja) 2019-01-17
AU2008290442A1 (en) 2009-02-26
MX2009013950A (es) 2010-03-09
US20140127202A1 (en) 2014-05-08
EP2173349B1 (de) 2011-03-09
IL240965A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
ATE500829T1 (de) Antitumor-kombinationen mit einem vegf-hemmenden mittel und irinotecan
ATE488227T1 (de) Feste zubereitung mit alogliptin und pioglitazon
ZA201204480B (en) Conjugate with target-finding ligand and use thereof
EP2187957A4 (de) Selektive cytopheresevorrichtungen und entsprechende verfahren
BRPI0812367A2 (pt) Dispositivos interoclusais e respectivos métodos de fabrico
PL2036882T3 (pl) Związki o jonach obojnaczych i ich zastosowanie
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2217371A4 (de) Katalysatoren und zugehörige verfahren
BRPI0809978A2 (pt) Dispositivos e métodos de dispensação de gotículas
EP2130575A4 (de) Wabensegment
ATE516797T1 (de) Topische polyaphron-zusammensetzung mit vitamin d und kortikosteroid
GB0707094D0 (en) Devices and methods for use in construction
EP2150571A4 (de) Polyalkylsilsesquioxanpartikel und verfahren zu ihrer herstellung
DE112008002974T8 (de) Masseanschlussfahne und Erdungsvorrichtung hiermit
ZA200909059B (en) Hydrocarbon mixtures and use thereof
PL2222981T3 (pl) Środki napędowe i napęd łańcuchowy
IL194751A0 (en) Drugs and uses
EP2081950A4 (de) Mit irinotecan-behandlung assoziierte expressionsprofile
IL208771A0 (en) Iminopyridine derivatives and use thereof
EP2247190A4 (de) Gummistrukturmischsysteme und verfahren
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
DE602007012059D1 (de) N und elektrofahrzeug
ZA201005482B (en) New macrolides and their use
DE102007013751B8 (de) Tiefpassfilter und Tiefpassfilter-Anordnung
IL206104A0 (en) Aminothiazoles and their uses